PreMD Inc (PME) Partners with AstraZeneca for Skin Test
Shares of PreMD Inc. (AMEX: PME) steadily rose in Monday's trading, settling at $1.90, up 82 cents or 76 percent, at the market's close. The move follows PreMD's news it struck a deal with AstraZeneca Pharmaceuticals (NYSE: AZN) to market and distribute a noninvasive skin cholesterol test, for now named PREVU.Symptoms of coronary heart disease are normally only noted in advanced stages of the disease - most individuals afflicted show no evidence until they are stricken with a "sudden" heart attack, the most common cause of death in men and women over 20 years of age. The PREVU skin test…